Absolument, parce que the report was up till 2006. The process improvements have now been in place since 2006. We are encouraging industry to come in. We have just set up an expert advisory committee that I talked about in our opening remarks that brings in industry at the beginning, during drug development, so we get the experience of their new drug, just as the U.S. does, just as Europe would do. Therefore, when the drug comes in for a submission, the time taken will be decreased and there will be increased efficiency in the regulatory process as we move forward.
On April 1st, 2008. See this statement in context.